CYT

Cyteir Therapeutics, Inc. Common Stock
CYT

Delisted

CYT was delisted on the 15th of March, 2024.

Back to rankings
 

About: Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.

Employees: 46

Healthcare Drug Manufacturers - General

Financial journalist opinion

Neutral
Business Wire
1 year ago
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced that it has formally notified The Nasdaq Stock Market (“Nasdaq”) of its intent to delist the Company's common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the “SEC”) relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the tradi.
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
See News Rankings
Charts implemented using Lightweight Charts™